<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR310.html">Part 310
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 310.503  Requirements regarding certain radioactive drugs.
                            </h3>
                            <p class="depth0"><em>(a)</em> On January 8, 1963 (28 FR 183), the Commissioner of Food and  Drugs exempted investigational radioactive new drugs from part 312 of  this chapter provided they were shipped in complete conformity with the  regulations issued by the Nuclear Regulatory Commission. This exemption  also applied to investigational radioactive biologics.</p><p class="depth0"><em>(b)</em> It is the opinion of the Nuclear Regulatory Commission, and the  Food and Drug Administration that this exemption should not apply for  certain specific drugs and that these drugs should be appropriately  labeled for uses for which safety and effectiveness can be demonstrated  by new drug applications or through licensing under the Public Health  Service Act (42 U.S.C. 262 et seq.) in the case of biologics. Continued  distribution under the investigational exemption when the drugs are  intended for established uses will not be permitted.</p><p class="depth0"><em>(c)</em> Based on its experience in regulating investigational  radioactive pharmaceuticals, the Nuclear Regulatory Commission has  compiled a list of reactor-produced isotopes for which it considers that  applicants may reasonably be expected to submit adequate evidence of  safety and effectiveness for use as recommended in appropriate labeling.  Such use may include, among others, the uses in this tabulation:  ------------------------------------------------------------------------</p><p class="depth0">Isotope              Chemical form                 Use ------------------------------------------------------------------------ Chromium 51...........  Chromate...............  Spleen scans.</p><p class="depth0">Do...................  ......do...............  Placenta localization.</p><p class="depth0">Do...................  ......do...............  Red blood cell labeling</p><p class="depth0">and survival studies.</p><p class="depth0">Do...................  Labeled human serum      Gastrointestinal</p><p class="depth0">albumin.                 protein loss studies.</p><p class="depth0">Do...................  ......do...............  Placenta localization.</p><p class="depth0">Do...................  Labeled red blood cells   Do. Cobalt 58 or Cobalt 60  Labeled cyanocobalamin.  Intestinal absorption</p><p class="depth0">studies. Gold 198..............  Colloidal..............  Liver scans.</p><p class="depth0">Do...................  ......do...............  Intracavitary treatment</p><p class="depth0">of pleural effusions</p><p class="depth0">and/or ascites.</p><p class="depth0">Do...................  ......do...............  Interstitial treatment</p><p class="depth0">of cancer. Iodine 131............  Iodide.................  Diagnosis of thyroid</p><p class="depth0">functions.</p><p class="depth0">Do...................  ......do...............  Thyroid scans.</p><p class="depth0">Do...................  ......do...............  Treatment of</p><p class="depth0">hyperthyroidism and/or</p><p class="depth0">cardiac dysfunction.</p><p class="depth0">Do...................  ......do...............  Treatment of thyroid</p><p class="depth0">carcinoma.</p><p class="depth0">Do...................  Iodinated human serum    Blood volume</p><p class="depth0">albumin.                 determinations.</p><p class="depth0">Do...................  ......do...............  Cisternography.</p><p class="depth0">Do...................  ......do...............  Brain tumor</p><p class="depth0">localization.</p><p class="depth0">Do...................  ......do...............  Placenta localization.</p><p class="depth0">Do...................  ......do...............  Cardiac scans for</p><p class="depth0">determination of</p><p class="depth0">pericardial effusions.</p><p class="depth0">Do...................  Rose Bengal............  Liver function studies.</p><p class="depth0">Do...................  ......do...............  Liver scans.</p><p class="depth0">Do...................  Iodopyracet, sodium      Kidney function studies</p><p class="depth0">iodohippurate, sodium    and kidney scans.</p><p class="depth0">diatrizoate,</p><p class="depth0">diatrizoate</p><p class="depth0">methylglucamine,</p><p class="depth0">sodium diprotrizoate,</p><p class="depth0">sodium acetrizoate, or</p><p class="depth0">sodium iothalamate.</p><p class="depth0">Do...................  Labeled fats and/or      Fat absorption studies.</p><p class="depth0">fatty acids.</p><p class="depth0">Do...................  Cholografin............  Cardiac scans for</p><p class="depth0">determination of</p><p class="depth0">pericardial effusions.</p><p class="depth0">Do...................  Macroaggregated          Lung scans.</p><p class="depth0">iodinated human serum</p><p class="depth0">albumin.</p><p class="depth0">Do...................  Colloidal                Liver scans.</p><p class="depth0">microaggregated human</p><p class="depth0">serum albumin. Iodine 125............  Iodide.................  Diagnosis of thyroid</p><p class="depth0">function.</p><p class="depth0">Do...................  Iodinated human serum    Blood volume</p><p class="depth0">albumin.                 determinations.</p><p class="depth0">Do...................  Rose Bengal............  Liver function studies.</p><p class="depth0">Do...................  Iodopyracet, sodium      Kidney function</p><p class="depth0">iodohippurate, sodium    studies.</p><p class="depth0">diatrizoate,</p><p class="depth0">diatrizoate methyl-</p><p class="depth0">glucamine, sodium</p><p class="depth0">diprotrizoate, sodium</p><p class="depth0">acetrizoate, or sodium</p><p class="depth0">iothalamate.</p><p class="depth0">Do...................  Labeled fats and/or      Fat absorption studies.</p><p class="depth0">fatty acids. Iron 59...............  Chloride, citrate and/   Iron turnover studies.</p><p class="depth0">or sulfate. Krypton 85............  Gas....................  Diagnosis of cardiac</p><p class="depth0">abnormalities. Mercury 197...........  Chlormerodrin..........  Kidney scans.</p><p class="depth0">Do...................  ......do...............  Brain scans.</p><p class="depth0">Mercury 203 \1\.......  ......do...............  Kidney scans.</p><p class="depth0">Do...................  ......do...............  Brain scans. Phosphorus 32.........  Soluble phosphate......  Treatment of</p><p class="depth0">polycythemia vera.</p><p class="depth0">Do...................  ......do...............  Treatment of leukemia</p><p class="depth0">and bone metastasis.</p><p class="depth0">Do...................  Colloidal chromic        Intracavitary treatment</p><p class="depth0">phosphate.               of pleural effusions</p><p class="depth0">and/or ascites.</p><p class="depth0">Do...................  ......do...............  Interstitial treatment</p><p class="depth0">of cancer. Potassium 42..........  Chloride...............  Potassium space</p><p class="depth0">studies. Selenium 75...........  Labeled methionine.....  Pancreas scans. Strontium 85..........  Nitrate or chloride....  Bone scans on patients</p><p class="depth0">with diagnosed cancer. Technetium 99m........  Pertechnetate..........  Brain scans.</p><p class="depth0">Do...................  ......do...............  Thyroid scans.</p><p class="depth0">Do...................  Sulfur colloid.........  Liver and spleen scans.</p><p class="depth0">Do...................  Pertechnetate..........  Placenta localization.</p><p class="depth0">Do...................  ......do...............  Blood pool scans.</p><p class="depth0">Do...................  ......do...............  Salivary gland scans.</p><p class="depth0">Do...................  Diethylenetri-amine      Kidney scans.</p><p class="depth0">pentaacetic acid</p><p class="depth0"><em>(DTPA)</em>. Xenon 133.............  Gas....................  Diagnosis of cardia</p><p class="depth0">abnormalities.</p><p class="depth0">Cerebral bloodflow</p><p class="depth0">studies. Pulmonary</p><p class="depth0">function studies.</p><p class="depth0">Muscle bloodflow</p><p class="depth0">studies. ------------------------------------------------------------------------ \1\ This item has been removed from the AEC list for kidney scans but is</p><p class="depth0">included as the requirements of this order are applicable.</p><p class="depth0"><em>(d)</em></p><p class="depth0"><em>(1)</em> In view of the extent of experience with the isotopes listed  in paragraph (c) of this section, the Nuclear Regulatory Commission and  the Food and Drug Administration conclude that such isotopes should not  be distributed under investigational-use labeling when they are actually  intended for use in medical practice.</p><p class="depth0"><em>(2)</em> The exemption referred to in paragraph (a) of this section, as  applied to any drug or biologic containing any of the isotopes listed in  paragraph (c) of this section, in the ``chemical form'' and intended for  the uses stated, is terminated on March 3, 1972, except as provided in  paragraph (d)(3) of this section.</p><p class="depth0"><em>(3)</em> The exemption referred to in paragraph (a) of this section, as  applied to any drug or biologic containing any of the isotopes listed in  paragraph (c) of this section, in the ``chemical form'' and intended for  the uses stated, for which drug a new drug application or a  ``Investigational New Drug Application'' was submitted prior to March 3,  1972, or for which biologic an application for product license or  ``Investigational New Drug Application'' was submitted prior to March 3,  1972, is terminated on August 20, 1976, unless an approvable notice was  issued on or before August 20, 1976, in which case the exemption is  terminated either upon the subsequent issuance of a nonapprovable notice  for the new drug application or on November 20, 1976, whichever occurs  first.</p><p class="depth0"><em>(e)</em> No exemption from section 505 of the act or from part 312 of  this chapter is in effect or has been in effect for radioactive drugs  prepared from accelerator-produced radioisotopes, naturally occurring  isotopes, or nonradioactive substances used in conjunction with  isotopes.</p><p class="depth0"><em>(f)</em></p><p class="depth0"><em>(1)</em> Based on its experience in regulating investigational  radioactive pharmaceuticals, the Nuclear Regulatory Commission has  compiled a list of reactor-produced isotopes for which it considers that  applicants may reasonably be expected to submit adequate evidence of  safety and effectiveness for use as recommended in appropriate labeling;  such use may include, among others, the uses in this tabulation:  ------------------------------------------------------------------------</p><p class="depth0">Isotope              Chemical form                 Use ------------------------------------------------------------------------ Fluorine 18...........  Fluoride...............  Bone imaging. Indium-113m...........  Diethylenetriamine       Brain imaging; kidney</p><p class="depth0">pentaacetic acid         imaging.</p><p class="depth0"><em>(DTPA)</em>.</p><p class="depth0">Do...................  Chloride...............  Placenta imaging; blood</p><p class="depth0">pool imaging. Technetium 99m........  Human serum albumin      Lung imaging.</p><p class="depth0">microspheres.</p><p class="depth0">Do...................  Diethylenetriamine       Kidney imaging; kidney</p><p class="depth0">pentaacetic acid (Sn).   function studies.</p><p class="depth0">Do...................  ......do...............  Brain imaging.</p><p class="depth0">Do...................  Polyphosphates.........  Bone imaging.</p><p class="depth0">Do...................  Technetated aggregated   Lung imaging.</p><p class="depth0">albumin (human).</p><p class="depth0">Do...................  Disodium etidronate....  Bone imaging. ------------------------------------------------------------------------</p><p class="depth0"><em>(2)</em> In view of the extent of experience with the isotopes listed in  paragraph (f)(1) of this section, the Nuclear Regulatory Commission and  the Food and Drug Administration conclude that they should not be  distributed under investigational-use labeling when they   are actually intended for use in medical practice.</p><p class="depth0"><em>(3)</em> Any manufacturer or distributor interested in continuing to ship  in interstate commerce drugs containing the isotopes listed in paragraph  (f)(1) of this section for any of the indications listed, shall submit,  on or before August 25, 1975 to the Center for Drug Evaluation and  Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD  20857, a new drug application or a ``Investigational New Drug  Application'' for each such drug for which the manufacturer or  distributor does not have an approved new drug application pursuant to  section 505(b) of the act. If the drug is a biologic, a  ``Investigational New Drug Application'' or an application for a license  under section 351 of the Public Health Service Act shall be submitted to  the Center for Biologics Evaluation and Research, Food and Drug  Administration, 8800 Rockville Pike, Bethesda, MD 20014, in lieu of any  submission to the Center for Drug Evaluation and Research.</p><p class="depth0"><em>(4)</em> The exemption referred to in paragraph (a) of this section, as  applied to any drug or biologic containing any of the isotopes listed in  paragraph (f)(1) of this section, in the ``chemical form'' and intended  for the uses stated, is terminated on August 26, 1975 except as provided  in paragraph (f)(5) of this section.</p><p class="depth0"><em>(5)</em></p><p class="depth0"><em>(i)</em> Except as provided in paragraph (f)(5)(ii) of this section,  the exemption referred to in paragraph (a) of this section, as applied  to any drug containing any of the isotopes listed in paragraph (f)(1) of  this section, in the ``chemical form'' and intended for the uses stated,  for which drug a new drug application or ``Investigational New Drug  Application'' was submitted to the Center for Drug Evaluation and  Research on or before August 25, 1975 is terminated on August 20, 1976,  unless an approvable notice was issued on or before August 20, 1976, in  which case the exemption is terminated either upon the subsequent  issuance of a nonapprovable notice for the new drug application or on  November 20, 1976, whichever occurs first.</p><p class="depth0"><em>(ii)</em> The exemption referred to in paragraph (a) of this section, as  applied to any biologic containing any of the isotopes listed in  paragraph (f)(1) of this section in the ``chemical form'' and intended  for the uses stated, for which biologic an application for product  license or ``Investigational New Drug Application'' was submitted to the  Center for Biologics Evaluation and Research on or before August 25,  1975 is terminated on October 20, 1976, unless an approvable notice was  issued on or before October 20, 1976, in which case the exemption is  terminated either upon the subsequent issuance of a nonapprovable notice  for the new drug application or on January 20, 1977, whichever occurs  first.</p><p class="depth0"><em>(g)</em> The exemption referred to in paragraph (a) of this section, as  applied to any drug intended solely for investigational use as part of a  research project, which use had been approved on or before July 25, 1975  in accordance with 10 CFR 35.11 (or equivalent regulation of an  Agreement State) is terminated on February 20, 1976 if the manufacturer  of such drug or the sponsor of the investigation of such drug submits on  or before August 25, 1975 to the Food and Drug Administration, Bureau of  Drugs, HFD-150, 5600 Fishers Lane, Rockville, MD 20857, the following  information:</p><p class="depth0"><em>(1)</em> The research project title;</p><p class="depth0"><em>(2)</em> A brief description of the purpose of the project;</p><p class="depth0"><em>(3)</em> The name of the investigator responsible;</p><p class="depth0"><em>(4)</em> The name and license number of the institution holding the  specific license under 10 CFR 35.11 (or equivalent regulation of an  Agreement State);</p><p class="depth0"><em>(5)</em> The name and maximum amount per subject of the radionuclide  used;</p><p class="depth0"><em>(6)</em> The number of subjects involved; and</p><p class="depth0"><em>(7)</em> The date on which the administration of the radioactive drugs is  expected to be completed.</p><p class="depth0"><em>(h)</em> The exemption referred to in paragraph (a) of this section, as  applied to any drug not referred to in paragraphs (d), (f), and (g) of  this section, is terminated on August 26, 1975.  [39 FR 11680, Mar. 29, 1974, as amended at 40 FR 31307, July 25, 1975;  40 FR 44543, Sept. 29, 1975; 41 FR 35171, Aug. 20, 1976; 41 FR 42947,  Sept. 29, 1976; 50 FR 8996, Mar. 6, 1985; 55 FR 11578, Mar. 29, 1990; 64  FR 56449, Oct. 20, 1999]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
